APTOSE BIOSCIENCES INC (APTO) Stock Price, Forecast & Analysis
NASDAQ:APTO • CA03835T4081
APTO Key Statistics, Chart & Performance
The current stock price of APTO is 1.71 USD. In the past month the price decreased by -33.98%. In the past year, price decreased by -95.87%.
APTO Technical Analysis
APTO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APTO. APTO has a bad profitability rating. Also its financial health evaluation is rather negative.
APTO Financial Highlights
Over the last trailing twelve months APTO reported a non-GAAP Earnings per Share(EPS) of -26.07. The EPS decreased by -237.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -327.57% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APTO Forecast & Estimates
8 analysts have analysed APTO and the average price target is 85.85 USD. This implies a price increase of 4920.47% is expected in the next year compared to the current price of 1.71.
APTO Ownership
APTO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.48 | 396.512B | ||
| AMGN | AMGEN INC | 16.63 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.39 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.19 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.62 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.06 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APTO
Company Profile
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 35 full-time employees. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Company Info
APTOSE BIOSCIENCES INC
251 Consumers Rd Suite 1105
North York ONTARIO M2J 4R3 CA
CEO: William G. Rice
Employees: 35
Phone: 16474799828
APTOSE BIOSCIENCES INC / APTO FAQ
What does APTOSE BIOSCIENCES INC do?
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. The company is headquartered in North York, Ontario and currently employs 35 full-time employees. The firm's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. Its lead clinical-stage compound Tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
Can you provide the latest stock price for APTOSE BIOSCIENCES INC?
The current stock price of APTO is 1.71 USD. The price decreased by -45.71% in the last trading session.
What is the dividend status of APTOSE BIOSCIENCES INC?
APTO does not pay a dividend.
How is the ChartMill rating for APTOSE BIOSCIENCES INC?
APTO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of APTOSE BIOSCIENCES INC (APTO)?
APTOSE BIOSCIENCES INC (APTO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-26.07).
Can you provide the market cap for APTOSE BIOSCIENCES INC?
APTOSE BIOSCIENCES INC (APTO) has a market capitalization of 4.36M USD. This makes APTO a Nano Cap stock.
Can you provide the upcoming earnings date for APTOSE BIOSCIENCES INC?
APTOSE BIOSCIENCES INC (APTO) will report earnings on 2025-05-12, after the market close.